New Predictive Biomarkers for Ovarian Cancer

Guest Editor:

Prof. Dr. Jill Marie Kolesar
Markey Cancer Center, University of Kentucky, Lexington, Lexington, KY, USA

Deadline for manuscript submissions:
closed (31 December 2020)

Message from the Guest Editor

The majority of women diagnosed with ovarian cancer present with advanced stage and are treated with standard chemotherapy. A number of novel predictive biomarkers, including tumor mutation burden, CCNE1 and other cell cycle genes, and BRCA1/2 and other DNA repair related genes, make a patient potentially eligible for a currently approved targeted therapy or immunotherapy. A number of targeted agents are in development for novel and existing biomarkers in ovarian cancer. The purpose of this Special Issue is to review new and emerging predictive biomarkers important in ovarian cancer that may make a patient eligible for treatment with novel targeted therapies or be a target for novel drug development.

Special Issue

diagnostics

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Contact Us